{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:20:52Z","timestamp":1785518452463,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,15]]},"DOI":"10.7759\/cureus.35030","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T21:06:42Z","timestamp":1676495202000},"source":"Crossref","is-referenced-by-count":8,"title":["Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety"],"prefix":"10.7759","author":[{"given":"Amr","family":"Elkammash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simpson Shiu Chung","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geethana","family":"Yogarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO. Ageing and health. (2022). Accessed: December 8, 2022: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad N","year":"2018","unstructured":"Conrad N, Judge A, Tran J, et al.. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018, 391:572-80. 10.1016\/S0140-6736(17)32520-5","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-014-0220-x","article-title":"Understanding the epidemic of heart failure: past, present, and future","volume":"11","author":"Dunlay SM","year":"2014","unstructured":"Dunlay SM, Roger VL. Understanding the epidemic of heart failure: past, present, and future. Curr Heart Fail Rep. 2014, 11:404-15. 10.1007\/s11897-014-0220-x","journal-title":"Curr Heart Fail Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth GA","year":"2015","unstructured":"Roth GA, Forouzanfar MH, Moran AE, et al.. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015, 372:1333-41. 10.1056\/NEJMoa1406656","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese G","year":"2017","unstructured":"Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017, 3:7-11. 10.15420\/cfr.2016:25:2","journal-title":"Card Fail Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.483","article-title":"Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review","volume":"18","author":"van Riet EE","year":"2016","unstructured":"van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016, 18:242-52. 10.1002\/ejhf.483","journal-title":"Eur J Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and Stroke Statistics-2018 update: a report from the American Heart Association","volume":"137","author":"Benjamin EJ","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW, et al.. Heart disease and Stroke Statistics-2018 update: a report from the American Heart Association. Circulation. 2018, 137:e67-e492. 10.1161\/CIR.0000000000000558","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-9842(02)00034-X","article-title":"Prevalence of chronic heart failure in Southwestern Europe: the EPICA study","volume":"4","author":"Ceia F","year":"2002","unstructured":"Ceia F, Fonseca C, Mota T, Morais H, Matias F, De Sousa A, Oliveira AG. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002, 4:531-9. 10.1016\/S1388-9842(02)00034-X","journal-title":"Eur J Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/agm2.12215","article-title":"Chinese expert consensus on the diagnosis and treatment of chronic heart failure in elderly patients (2021)","volume":"5","author":"Wang X","year":"2022","unstructured":"Wang X, Zhang C. Chinese expert consensus on the diagnosis and treatment of chronic heart failure in elderly patients (2021). Aging Med (Milton). 2022, 5:78-93. 10.1002\/agm2.12215","journal-title":"Aging Med (Milton)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock SJ","year":"2013","unstructured":"Pocock SJ, Ariti CA, McMurray JJ, et al.. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013, 34:1404-13. 10.1093\/eurheartj\/ehs337","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2016.07.030","article-title":"All-payer analysis of heart failure hospitalization 30-day readmission: comorbidities matter","volume":"130","author":"Davis JD","year":"2017","unstructured":"Davis JD, Olsen MA, Bommarito K, LaRue SJ, Saeed M, Rich MW, Vader JM. All-payer analysis of heart failure hospitalization 30-day readmission: comorbidities matter. Am J Med. 2017, 130:93.e9-e28. 10.1016\/j.amjmed.2016.07.030","journal-title":"Am J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02935-x","article-title":"Heart failure with preserved ejection fraction based on aging and comorbidities","volume":"19","author":"Lin Y","year":"2021","unstructured":"Lin Y, Fu S, Yao Y, Li Y, Zhao Y, Luo L. Heart failure with preserved ejection fraction based on aging and comorbidities. J Transl Med. 2021, 19:291. 10.1186\/s12967-021-02935-x","journal-title":"J Transl Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.04.037","article-title":"Empagliflozin and elderly patients with preserved ejection fraction heart failure: is age just a number?","volume":"80","author":"Sauer AJ","year":"2022","unstructured":"Sauer AJ. Empagliflozin and elderly patients with preserved ejection fraction heart failure: is age just a number?. J Am Coll Cardiol. 2022, 80:19-21. 10.1016\/j.jacc.2022.04.037","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1742395320983871","article-title":"Challenges in the management of people with heart failure with preserved ejection fraction (HFpEF) in primary care: a qualitative study of general practitioner perspectives","volume":"18","author":"Hossain MZ","year":"2022","unstructured":"Hossain MZ, Chew-Graham CA, Sowden E, Blakeman T, Wellwood I, Tierney S, Deaton C. Challenges in the management of people with heart failure with preserved ejection fraction (HFpEF) in primary care: a qualitative study of general practitioner perspectives. Chronic Illn. 2022, 18:410-25. 10.1177\/1742395320983871","journal-title":"Chronic Illn"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.11909\/j.issn.1671-5411.2016.12.008","article-title":"Cardiac drug therapy-considerations in the elderly","volume":"13","author":"Ayan M","year":"2016","unstructured":"Ayan M, Pothineni NV, Siraj A, Mehta JL. Cardiac drug therapy-considerations in the elderly. J Geriatr Cardiol. 2016, 13:992-7. 10.11909\/j.issn.1671-5411.2016.12.008","journal-title":"J Geriatr Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway NR","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022, 18:1230. 10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel O","year":"2017","unstructured":"Chioncel O, Lainscak M, Seferovic PM, et al.. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017, 19:1574-85. 10.1002\/ejhf.813","journal-title":"Eur J Heart Fail"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez E","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, et al.. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015, 36:2585-94. 10.1093\/eurheartj\/ehv338","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.08.048","article-title":"Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins","volume":"68","author":"Kotecha D","year":"2016","unstructured":"Kotecha D, Lam CS, Van Veldhuisen DJ, Van Gelder IC, Voors AA, Rienstra M. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J Am Coll Cardiol. 2016, 68:2217-28. 10.1016\/j.jacc.2016.08.048","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2015.01.009","article-title":"Hospitalizations and prognosis in elderly patients with heart failure and preserved ejection fraction: time to treat the whole patient","volume":"3","author":"Kitzman DW","year":"2015","unstructured":"Kitzman DW, Upadhya B, Reeves G. Hospitalizations and prognosis in elderly patients with heart failure and preserved ejection fraction: time to treat the whole patient. JACC Heart Fail. 2015, 3:442-4. 10.1016\/j.jchf.2015.01.009","journal-title":"JACC Heart Fail"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd9080241","article-title":"Effects of exercise on heart failure with preserved ejection fraction: an updated review of literature","volume":"9","author":"Crisci G","year":"2022","unstructured":"Crisci G, De Luca M, D'Assante R, et al.. Effects of exercise on heart failure with preserved ejection fraction: an updated review of literature. J Cardiovasc Dev Dis. 2022, 9:241. 10.3390\/jcdd9080241","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026141","article-title":"Physical rehabilitation for older patients hospitalized for heart failure","volume":"385","author":"Kitzman DW","year":"2021","unstructured":"Kitzman DW, Whellan DJ, Duncan P, et al.. Physical rehabilitation for older patients hospitalized for heart failure. N Engl J Med. 2021, 385:203-16. 10.1056\/NEJMoa2026141","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2015.06.018","article-title":"Safety of reduced anti-thrombotic strategies in HeartMate II patients: a one-year analysis of the US-TRACE Study","volume":"34","author":"Katz JN","year":"2015","unstructured":"Katz JN, Adamson RM, John R, et al.. Safety of reduced anti-thrombotic strategies in HeartMate II patients: a one-year analysis of the US-TRACE Study. J Heart Lung Transplant. 2015, 34:1542-8. 10.1016\/j.healun.2015.06.018","journal-title":"J Heart Lung Transplant"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","article-title":"Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction","volume":"7","author":"Adamson PB","year":"2014","unstructured":"Adamson PB, Abraham WT, Bourge RC, et al.. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014, 7:935-44. 10.1161\/CIRCHEARTFAILURE.113.001229","journal-title":"Circ Heart Fail"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00723-0","article-title":"Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial","volume":"387","author":"Abraham WT","year":"2016","unstructured":"Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet. 2016, 387:453-61. 10.1016\/S0140-6736(15)00723-0","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016760","article-title":"Impact of interatrial shunts on invasive hemodynamics and exercise tolerance in patients with heart failure","volume":"9","author":"Griffin JM","year":"2020","unstructured":"Griffin JM, Borlaug BA, Komtebedde J, et al.. Impact of interatrial shunts on invasive hemodynamics and exercise tolerance in patients with heart failure. J Am Heart Assoc. 2020, 9:e016760. 10.1161\/JAHA.120.016760","journal-title":"J Am Heart Assoc"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032094","article-title":"Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (reduce lap-HF I [reduce elevated left atrial pressure in patients with heart failure]): a phase 2, randomized, sham-controlled trial","volume":"137","author":"Feldman T","year":"2018","unstructured":"Feldman T, Mauri L, Kahwash R, et al.. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (reduce lap-HF I [reduce elevated left atrial pressure in patients with heart failure]): a phase 2, randomized, sham-controlled trial. Circulation. 2018, 137:364-75. 10.1161\/CIRCULATIONAHA.117.032094","journal-title":"Circulation"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00016-2","article-title":"Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial","volume":"399","author":"Shah SJ","year":"2022","unstructured":"Shah SJ, Borlaug BA, Chung ES, et al.. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet. 2022, 399:1130-40. 10.1016\/S0140-6736(22)00016-2","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann F","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG, et al.. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013, 309:781-91. 10.1001\/jama.2013.905","journal-title":"JAMA"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)","volume":"53","author":"van Veldhuisen DJ","year":"2009","unstructured":"van Veldhuisen DJ, Cohen-Solal A, B\u00f6hm M, et al.. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009, 53:2150-8. 10.1016\/j.jacc.2009.02.046","journal-title":"J Am Coll Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfr161","article-title":"Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study","volume":"14","author":"Conraads VM","year":"2012","unstructured":"Conraads VM, Metra M, Kamp O, et al.. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012, 14:219-25. 10.1093\/eurjhf\/hfr161","journal-title":"Eur J Heart Fail"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)","volume":"15","author":"Yamamoto K","year":"2013","unstructured":"Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013, 15:110-8. 10.1093\/eurjhf\/hfs141","journal-title":"Eur J Heart Fail"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland JG","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006, 27:2338-45. 10.1093\/eurheartj\/ehl250","journal-title":"Eur Heart J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.109.898916","article-title":"A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility","volume":"3","author":"Kitzman DW","year":"2010","unstructured":"Kitzman DW, Hundley WG, Brubaker PH, Morgan TM, Moore JB, Stewart KP, Little WC. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail. 2010, 3:477-85. 10.1161\/CIRCHEARTFAILURE.109.898916","journal-title":"Circ Heart Fail"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf S","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, et al.. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003, 362:777-81. 10.1016\/S0140-6736(03)14285-7","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie BM","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, et al.. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008, 359:2456-67. 10.1056\/NEJMoa0805450","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2007.117978","article-title":"The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction","volume":"94","author":"Yip GW","year":"2008","unstructured":"Yip GW, Wang M, Wang T, et al.. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008, 94:573-80. 10.1136\/hrt.2007.117978","journal-title":"Heart"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.628347","article-title":"Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial","volume":"114","author":"Ahmed A","year":"2006","unstructured":"Ahmed A, Rich MW, Fleg JL, et al.. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006, 114:397-403. 10.1161\/CIRCULATIONAHA.106.628347","journal-title":"Circulation"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif ME","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al.. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021, 27:1954-60. 10.1038\/s41591-021-01536-x","journal-title":"Nat Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022, 387:1089-98. 10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt DL","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, et al.. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021, 384:129-39. 10.1056\/NEJMoa2030186","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt DL","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al.. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021, 384:117-28. 10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon SD","year":"2019","unstructured":"Solomon SD, McMurray JJ, Anand IS, et al.. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019, 381:1609-20. 10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvx020","article-title":"Loop diuretics for chronic heart failure: a foe in disguise of a friend?","volume":"4","author":"Kapelios CJ","year":"2018","unstructured":"Kapelios CJ, Malliaras K, Kaldara E, Vakrou S, Nanas JN. Loop diuretics for chronic heart failure: a foe in disguise of a friend?. Eur Heart J Cardiovasc Pharmacother. 2018, 4:54-63. 10.1093\/ehjcvp\/pvx020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvy001","article-title":"Relationship of loop diuretic use with exercise intolerance in heart failure with preserved ejection fraction","volume":"4","author":"Montero D","year":"2018","unstructured":"Montero D, Haider T. Relationship of loop diuretic use with exercise intolerance in heart failure with preserved ejection fraction. Eur Heart J Cardiovasc Pharmacother. 2018, 4:138-41. 10.1093\/ehjcvp\/pvy001","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3390\/medicines7050030","article-title":"Heart failure drug class effects on 30-day readmission rates in patients with heart failure with preserved ejection fraction: a retrospective single center study","volume":"7","author":"Parajuli P","year":"2020","unstructured":"Parajuli P, Lara-Garcia OE, Regmi MR, Skoza W, Bhattarai M, Kulkarni A, Robinson RL. Heart failure drug class effects on 30-day readmission rates in patients with heart failure with preserved ejection fraction: a retrospective single center study. Medicines (Basel). 2020, 7:30. 10.3390\/medicines7050030","journal-title":"Medicines (Basel)"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF)","volume":"17","author":"Deswal A","year":"2011","unstructured":"Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail. 2011, 17:634-42. 10.1016\/j.cardfail.2011.04.007","journal-title":"J Card Fail"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2012.08.001","article-title":"Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction","volume":"1","author":"Patel K","year":"2013","unstructured":"Patel K, Fonarow GC, Kitzman DW, et al.. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2013, 1:40-7. 10.1016\/j.jchf.2012.08.001","journal-title":"JACC Heart Fail"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.08.017","article-title":"MRAs in elderly HF patients: individual patient-data meta-analysis of RALES, EMPHASIS-HF, and TOPCAT","volume":"7","author":"Ferreira JP","year":"2019","unstructured":"Ferreira JP, Rossello X, Eschalier R, et al.. MRAs in elderly HF patients: individual patient-data meta-analysis of RALES, EMPHASIS-HF, and TOPCAT. JACC Heart Fail. 2019, 7:1012-21. 10.1016\/j.jchf.2019.08.017","journal-title":"JACC Heart Fail"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(02)00173-6","article-title":"Beta-blockers for heart failure: why, which, when, and where","volume":"87","author":"Cleland JGF","year":"2003","unstructured":"Cleland JGF. Beta-blockers for heart failure: why, which, when, and where. Med Clin North Am. 2003, 87:339-71. 10.1016\/S0025-7125(02)00173-6","journal-title":"Med Clin North Am"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-10013-5","article-title":"Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials","volume":"26","author":"Fukuta H","year":"2021","unstructured":"Fukuta H, Goto T, Wakami K, Kamiya T, Ohte N. Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2021, 26:165-71. 10.1007\/s10741-020-10013-5","journal-title":"Heart Fail Rev"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.09.031","article-title":"Clinical effectiveness of beta-blockers in heart failure: findings from the optimize-HF (organized program to initiate lifesaving treatment in hospitalized patients with heart failure) registry","volume":"53","author":"Hernandez AF","year":"2009","unstructured":"Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the optimize-HF (organized program to initiate lifesaving treatment in hospitalized patients with heart failure) registry. J Am Coll Cardiol. 2009, 53:184-92. 10.1016\/j.jacc.2008.09.031","journal-title":"J Am Coll Cardiol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5011-1025","article-title":"Sacubitril\/Valsartan","volume":"50","author":"Cada DJ","year":"2015","unstructured":"Cada DJ, Baker DE, Leonard J. Sacubitril\/Valsartan. Hosp Pharm. 2015, 50:1025-36. 10.1310\/hpj5011-1025","journal-title":"Hosp Pharm"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"28","year":"2022","unstructured":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure. J Card Fail. 2022, 28.e1-e167. 10.1016\/j.cardfail.2022.02.010","journal-title":"J Card Fail"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac201","article-title":"The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus","volume":"51","author":"Evans M","year":"2022","unstructured":"Evans M, Morgan AR, Davies S, Beba H, Strain WD. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing. 2022, 51:1-8. 10.1093\/ageing\/afac201","journal-title":"Age Ageing"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/136499-management-of-heart-failure-with-preserved-ejection-fraction-in-elderly-patients-effectiveness-and-safety","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:37Z","timestamp":1707508357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/136499-management-of-heart-failure-with-preserved-ejection-fraction-in-elderly-patients-effectiveness-and-safety"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":57,"URL":"https:\/\/doi.org\/10.7759\/cureus.35030","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,15]]}}}